Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor- agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REZDIFFRA  TREATMENT SIGNIFICANTLY IMPROVED LIVER STIFFNESS, FIBROSIS BIOMARKERS, AND MARKERS OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION RISK IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS REZDIFFRA ALSO IMPROVED DISEASE-SPECIFIC QUALITY OF LIFE MEASURES IN PATIENTS WITH AND WITHOUT CIRRHOSIS, WITH SUSTAINED EFFECT THROUGH TWO YEARS OF TREATMENT NEW ANALYSIS EXAMINING EFFECTS OF REZDIFFRA TREATMENT INTERRUPTION UNDERSCORES THE NEED FOR SUSTAINED THERAPY TO PREVENT DISEASE PROGRESSION CONSHOHOCKEN, PA., NOV. 10, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED POSITIVE TWO-YEAR DATA FROM THE OPEN-LABEL COMPENSATED MASH CIRRHOSIS (F4C) ARM OF THE PHASE 3 MAESTRO-NAFLD-1 TRIAL, EVALUATING THE USE OF REZDIFFRA IN AN ADVANCED, DIFFICULT-TO-TREAT PATIENT POPULATION WITH NO APPROVED THERAPIES.

MADRIGAL PRESENTS NEW DATA DEMONSTRATING REZDIFFRA (RESMETIROM) SIGNIFICANTLY IMPROVED MULTIPLE NONINVASIVE IMAGING TESTS AND BIOMARKERS IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS

CONSHOHOCKEN, PA., NOV. 06, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON NOVEMBER 1, 2025 TO 18 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN.

MADRIGAL PHARMACEUTICALS ANNOUNCES GRANTS OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

THIRD -QUARTER 2025 REZDIFFRA (RESMETIROM) NET SALES OF $287.3 MILLION AS OF SEPTEMBER30, 2025 , MORE THAN 29,500 PATIENTS ON REZDIFFRA CLOSED GLOBAL LICENSING AGREEMENT WITH CSPC PHARMA TO ADD ORAL GLP-1 TO PIPELINE NEW ORANGE BOOK LISTED PATENT FOR REZDIFFRA PROVIDING PROTECTION INTO 2045 LAUNCHED REZDIFFRA IN GERMANY FOLLOWING EUROPEAN COMMISSION APPROVAL REPORTS CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES OF $1.1 BILLION AS OF SEPT.30, 2025 COMPANY TO HOST CONFERENCE CALL TODAY, NOV. 4, 2025, AT 8 A.M.

MADRIGAL PHARMACEUTICALS REPORTS THIRD-QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

TWO ORAL PRESENTATIONS TO HIGHLIGHT BIOMARKER, IMAGING AND QUALITY-OF-LIFE DATA FROM THE OPEN-LABEL COMPENSATED MASH CIRRHOSIS (F4C) ARM OF THE PHASE 3 MAESTRO-NAFLD-1 TRIAL OF REZDIFFRA POSTER OF DISTINCTION EXAMINES THE IMPACT OF REZDIFFRA INTERRUPTION ON PATIENTS, UNDERSCORING THE NEED FOR CONTINUED TREATMENT TO PREVENT DISEASE PROGRESSION FURTHER POSTER PRESENTATIONS EXAMINE EARLY REAL-WORLD EXPERIENCE WITH REZDIFFRA AND THE CLINICAL BURDEN OF MASH CONSHOHOCKEN, PA., OCT. 28, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED MULTIPLE MASH AND REZDIFFRA (RESMETIROM) DATA PRESENTATIONS AT THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) THE LIVER MEETING, TAKING PLACE FROM NOVEMBER 7-11, 2025, IN WASHINGTON, D.C.

MADRIGAL TO PRESENT NEW DATA FROM THE COMPANY'S MASH PROGRAM AT AASLD'S THE LIVER MEETING 2025

CONSHOHOCKEN, PA., OCT. 22, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), ANNOUNCED TODAY THAT IT WILL RELEASE ITS THIRD-QUARTER 2025 FINANCIAL RESULTS ON TUESDAY, NOV. 4, 2025, PRIOR TO THE OPEN OF THE U.S. FINANCIAL MARKETS.

MADRIGAL PHARMACEUTICALS TO RELEASE THIRD-QUARTER 2025 FINANCIAL RESULTS AND HOST WEBCAST ON NOVEMBER 4, 2025

CONSHOHOCKEN, PA., OCT. 21, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON OCTOBER 15, 2025 TO 19 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN.

CONSHOHOCKEN, PA., OCT. 07, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON OCTOBER 1, 2025 TO 27 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., SEPT. 18, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON SEPTEMBER 15, 2025 TO 76 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON SEPTEMBER 1, 2025 TO 17 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CONSHOHOCKEN, PA., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTH CARE CONFERENCE ON MONDAY, SEPT.

MADRIGAL PHARMACEUTICALS TO PARTICIPATE IN MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

CONSHOHOCKEN, PA., AUG. 21, 2025 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING NOVEL THERAPEUTICS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT IT GRANTED EQUITY AWARDS ON AUGUST 15, 2025 TO 11 NEW NON-EXECUTIVE EMPLOYEES AS EQUITY INDUCEMENT AWARDS UNDER THE TERMS OF MADRIGAL'S 2025 INDUCEMENT PLAN. THE EQUITY AWARDS WERE APPROVED BY MADRIGAL'S INDEPENDENT COMPENSATION COMMITTEE IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

Madrigal Pharmaceuticals, Inc.

MDGL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Madrigal Pharmaceuticals, Inc.

MDGL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MDGL